Pliant Therapeutics (NASDAQ:PLRX) Downgraded to Sector Perform Rating by Royal Bank of Canada
Pliant Therapeutics (NASDAQ:PLRX – Get Free Report) was downgraded by analysts at Royal Bank of Canada from an “outperform” rating to a “sector perform” rating in a report issued on Monday, MarketBeat Ratings reports. They presently have a $4.00 price objective on the stock, down from their prior price objective of $45.00. Royal Bank of […]
Pliant Therapeutics (NASDAQ:PLRX – Get Free Report) was downgraded by analysts at Royal Bank of Canada from an “outperform” rating to a “sector perform” rating in a report issued on Monday, MarketBeat Ratings reports. They presently have a $4.00 price objective on the stock, down from their prior price objective of $45.00. Royal Bank of […]
